RayKnowChina Research Map
Shortlist0

RecruitingGastrointestinal stromal tumourPhase 2

Registered title, quoted from ClinicalTrials.gov

Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors

An open trial on gastrointestinal stromal tumour, registered on ClinicalTrials.gov. Led by First Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT04933669, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. Preoperative histologically confirmed primary gastrointestinal stromal tumor

    Inclusion criterion 1

  3. Performance status: Eastern Cooperative Oncology Group (ECOG) 0-1

    Inclusion criterion 6

  4. Gene mutation test report including c-kit exons 9,11,13 and 17 and platelet-derived growth factor receptor alpha (PDGFRA) exons 12 and 18

    Inclusion criterion 3

    Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT)>2.5×ULN(upper limit of normal),or Total bilirubin (TBIL)>1.5×ULN,or Creatinine (Cr)>1.0×ULN

    Exclusion criterion 3

    Absolute neutrophil count (ANC) < 1.5 × 10 \^ 9 / L;or Platelet count (PLT) < 75 × 10 \^ 9 / L;or Hemoglobin (Hb) ≥ 90 g / L

    Exclusion criterion 4

  5. positive Human Immunodeficiency Virus (HIV) antibody

    Exclusion criterion 8

  6. Pregnant or lactating women or have fertility without taking contraception

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04933669, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Preoperative histologically confirmed primary gastrointestinal stromal tumor
  • Tumor must stain positive for c-Kit (CD117) and/or discovered on gist-1 (DOG-1) by immunohistochemistry
  • Gene mutation test report including c-kit exons 9,11,13 and 17 and platelet-derived growth factor receptor alpha (PDGFRA) exons 12 and 18
  • High risk GIST (as modified National Institutes of Health (NIH) 2008): stomach (maximum tumor diameter> 10.0cm), nonstomach (maximum tumor diameter> 5.0cm)
  • Gender is not limited. Age: ≥ 18 years and ≤ 80 years old
  • Performance status: Eastern Cooperative Oncology Group (ECOG) 0-1
  • Patient had informed consent and signed a written consent form

Exclusion Criteria:

  • Asp842Val (D842V) mutation in Exon 18 of PDGFRA gene, or wild type (c-kit exon 9,11,13,17, and PDGFRA Exon 12,18), or c-kit exon 9 mutation
  • Treated with tyrosine kinase inhibitors including Imatinib
  • Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT)>2.5×ULN(upper limit of normal),or Total bilirubin (TBIL)>1.5×ULN,or Creatinine (Cr)>1.0×ULN
  • Absolute neutrophil count (ANC) < 1.5 × 10 \^ 9 / L;or Platelet count (PLT) < 75 × 10 \^ 9 / L;or Hemoglobin (Hb) ≥ 90 g / L
  • Previous or concurrent other active malignant tumors (except for basal cell carcinoma of the skin, or cervical cancer in situ that has undergone curative therapy)
  • Distant metastases are present
  • Any of the following conditions during the 12 months prior to entry: myocardial infarction, severe / unstable angina, coronary artery / peripheral artery bypass surgery, symptomatic congestive heart failure, or cerebrovascular accidents
  • positive Human Immunodeficiency Virus (HIV) antibody
  • Currently participating in other clinical trials
  • Pregnant or lactating women or have fertility without taking contraception
  • Suffering from other serious acute and chronic physical or mental problems, or abnormal laboratory tests, will increase the risk of participation or drug use, or interfere with the judgment of the findings, judged by the researchers as participate in the study

Quoted from ClinicalTrials.gov, NCT04933669, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04933669, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04933669